Nicox European Patent Seals ZERVIATE Major Market Coverage to 2030

www.nicox.com Press Release Nicox European Patent Seals ZERVIATE Major Market Coverage to 2030  Patent coverage for ZERVIATE® (cetirizine ophthalmic solution), 0.24% in Europe until 2030 January 5, 2022 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that patent EP2408453, covering the company’s product ZERVIATE® (cetirizine ophthalmic solution), 0.24%, has been issued by the European Patent Office (EPO). The patent covers the formulation of ZERVIATE which is commercialized in the U.S. by our exclusive U.S. licensee Eyevance Pharmaceuticals, and its use in the treatment of the symptoms of allergic conjunctivitis or allergic rhinoconjunctivitis. The prescription market for allergic conjunctivitis products in Europe, Easter n Europe and Turkey was estimated by IQVIA as around €2 60 million in 2020. The European Pate nt grants exclusivity until 2030, meaning that the ZERVIATE formulation is protected by granted patents in the U.S. to 2032, and in Europe, Japan and Canada to 2030. “The European patent grant means that ZERVIATE now has patent coverage in all the principal pharmaceutical markets worldwide. We are working with our existing partners to bring ZERVIATE to commercialization and continue to look for additional licensing opportunities to broaden the ZERVIATE franchise.” said Gavin Spencer, Chief Business Officer of Nicox. “The data package from the U.S. New Drug Application facilitates further approvals of ZERVIATE. We also collaborate with partners to ensure any necessary additional regulatory data are generated. In China, where ZERVIATE is partnered with Ocumension Therapeutics, for instance, pivotal Phase 3 data is being gathered to support local regulatory approval.” ZERVIATE is commercialized in the U.S. by our exclusive U.S. partner Eyevance Pharmaceuticals, a wholly-owned subsidiary of Santen Pharmaceutical Co., Ltd of Japan. ZERVIATE is also exclusively licensed to Ocumension Therapeutics for development and commercialization in the Chinese and the majority of the Southeast Asian markets, to Samil Pharmaceutical in South Korea, to ITROM Pharmaceutical Group in certain Gulf and Arab markets, and to Laboratorios Grin in Mexico. About Nicox Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE ® in allergic conjunctivitis, licensed i n multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. For more information on Nicox, its products or pipeline, please visit: www.nicox.com. Analyst coverage Bryan, Garnier & Co Dylan van Haaften Paris, France Edison Investment Research Pooya Hemami London, UK H.C. Wainwright & Co Yi Chen New York, U.S. Kepler Cheuvreux Damien Choplain Paris, France www.nicox.com The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or t o update the information contained in analyst reports. Contacts Nicox Gavin Spencer Executive Vice President, Chief Business Officer & Head of Corporate Development T +33 (0)4 97 24 53 00 [email protected] Investors & Media United States & Europe LifeSci Advisors, LLC Sandya von der Weid T +41 78 680 05 38 [email protected] Media France LifeSci Advisors, LLC Sophie Baumont T +33 (0)6 27 74 74 49 [email protected] Forward-Looking Statements The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties th at could cause actual results to differ materially from those described in the forward -looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide upd ates or to revise any forward-looking statements. Risks factors which are likely to have a material effect on Nicox’s business are presented in the 3 rd chapter of the ‘ Document d’enregistrement universel, rapport financier annuel et rapport de gestion 2020’ filed with the French Autorité des Marchés Financiers (AMF) on March 1, 2021 and in the 2 nd chapter of the amendment to the “ Document d’Enregistrement Universel, rapport financier annuel et rapport de gestion 2020” filed with the AMF on December 9, 2021 which are available on Nicox’s website (www.nicox.com). Nicox S.A. Drakkar 2 Bât D, 2405 route des Dolines CS 10313, Sophia Antipolis 06560 Valbonne, France T +33 (0)4 97 24 53 00 F +33 (0)4 97 24 53 99

The release as fetched from its publisher. nicox.com ↗